HELEN HESLOP to Graft Rejection
This is a "connection" page, showing publications HELEN HESLOP has written about Graft Rejection.
Connection Strength
0.487
-
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006 Nov 01; 108(9):2942-9.
Score: 0.183
-
Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021 01; 39(1):56-63.
Score: 0.121
-
XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Bone Marrow Transplant. 1994 May; 13(5):571-5.
Score: 0.078
-
Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1298-304.
Score: 0.054
-
Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program. 2005; 260-6.
Score: 0.041
-
Allogeneic bone marrow transplantation at Christchurch 1979-1985. N Z Med J. 1986 May 14; 99(801):318-21.
Score: 0.011